Pharma Launch Excellence Summit Main Conference Day 2: Thursday 3rd December

Pharma Launch Excellence Summit Main Conference Day 2: Thursday 3rd December 

8:00 am - 9:00 am Registration

img

Sophie Hoehlinger

Former Head of Global Launch Excellence
UCB

9:00 am - 9:30 am Panel Discussion: The Future of Drug Pricing in 2027 & Beyond: Learning How the Most Favoured Nation Policy will Influence the Next Wave of Launches from a Commercial Standpoint

Eugene Osei-Bonsu - Senior Director - Neuroscience Marketing and Strategy Lead - Global Portfolio D, Takeda
With the onset of The Most Favoured Nation policy poised to reshape global pricing strategies, launch teams must prepare for a changing market access landscape. This session will explore the policy's implications for launch sequencing, pricing, and commercial strategy across Europe and beyond.

• Understanding the latest MFN policy developments and what they mean for launch excellence teams around the globe
• Mapping the timeline and anticipated implementation of MFN to understand how it will affect global launches in 2027 and beyond
• Adapting launch sequencing, pricing, and market access strategies to capitalise on opportunities created by MFN policies
img

Eugene Osei-Bonsu

Senior Director - Neuroscience Marketing and Strategy Lead - Global Portfolio D
Takeda

9:30 am - 10:00 am Case Study Presentation: Exploring the EU Pharmaceutical Package to Understand What It Means for Your Next Launch

Ana Mitic - Associate Director Launch Excellence - Marketing Europe, Neuro-Psychiatry, Teva
Tirzah Kijzer - Senior Director Marketing & Launch Excellence, Teva Israel Ltd

The EU Pharmaceutical Package is one of the most comprehensive reforms of EU pharmaceutical legislation in over 20 years. This session will explore how launch excellence teams adapt their strategies to navigate regulatory change, accelerate approvals, and maintain a competitive advantage across European markets. 

• Learning how companies are negotiating policy changes to support launch strategies in an evolving regulatory landscape
• Exploring varying regulatory pathways, reimbursement pathways and international recognition procedures and what it means for future launches
• Leveraging prior approvals from trusted reference regulatory authorities to accelerate market authorisation of medicine
• Hearing a real-world case study on a pediatric launch by Teva Pharmaceuticals

img

Ana Mitic

Associate Director Launch Excellence - Marketing Europe, Neuro-Psychiatry
Teva

img

Tirzah Kijzer

Senior Director Marketing & Launch Excellence
Teva Israel Ltd

10:00 am - 10:30 am Inspiros Consulting Presentation

10:30 am - 11:00 am Networking Break

11:00 am - 11:30 am Panel Discussion: Course Correcting Launches in Real Time: How to Transform Early Warning Signals into Measurable Performance Improvements

Ester Guiu - Director - Business & Launch Excellence, Global Commercial Operations, Almirall

The first months following launch present a critical window to influence long-term success. Organisations that establish the right KPIs, identify performance signals early, and respond with agility are better positioned to address issues before they impact commercial outcomes. Converting launch data into rapid, coordinated action is essential to maximising product uptake and achieving launch objectives. 

• Establishing meaningful KPIs to monitor early launch performance during the critical post launch optimisation window
• Detecting performance signals to diagnose root causes of launch failures quickly
• Implementing rapid mitigation strategies to course correct and optimise launch execution in real time

img

Ester Guiu

Director - Business & Launch Excellence, Global Commercial Operations
Almirall

11:30 am - 12:00 pm Case Study Presentation: Launch Performance Optimisation: Embedding a Data-Driven Culture for Smarter Decision-Making

Jolanda Koenders - Head of Launch Excellence and New Product Planning, Central South East Europe, Takeda

Successful launches depend on more than a strong strategy, they require organisations to continuously measure performance, generate actionable insights and align teams around shared objectives. As AI and advanced analytics become increasingly accessible, leaders have a greater opportunity to create a culture where tracking, planning and data-driven decision-making drive better launch outcomes across both global and local markets. 

• Learning how to build a culture of continuous launch tracking to improve launch
performance
• Hearing how to leverage AI and data to generate faster, actionable launch insights
• Creating a plan to align global and local teams around shared launch performance
metrics to make launch execution easy

img

Jolanda Koenders

Head of Launch Excellence and New Product Planning, Central South East Europe
Takeda

12:00 pm - 1:00 pm Networking Lunch Break

1:00 pm - 1:30 pm Panel Discussion: Building a Supply Chain Strategy to Maximise Your Product’s Chance of Being “First-to-Market”

Supply chain excellence is no longer just an operational priority. It is a competitive advantage that can determine launch success. This session will explore how early supply chain planning and cross-functional alignment can accelerate market entry, strengthen launch readiness, and improve patient access.

• Learning how to leverage the supply chain to gain a competitive advantage for your next launch
• Discovering how to streamline supply chain operations to accelerate market entry and ensure timely patient access to therapy
• Navigating the complexities of global supply chains by aligning your launch team's goals with the supply chain function early to ensure readiness across diverse markets and distribution networks

1:30 pm - 2:00 pm Interactive Session: Session details to be announced


2:00 pm - 2:30 pm Networking Break

2:30 pm - 4:30 pm Roundtable Discussion: Functional Roles, Contribution and Accountability for Cross- Functionally Aligned Collaboration and Measurable Launch Performance

Troels Sørensen - Global Head Clinical Practice, Boehringer Ingelheim
img

Troels Sørensen

Global Head Clinical Practice
Boehringer Ingelheim